OmniAb Investor Conference Presentation Deck
Recent News Flow from Partners
SELECT RECENT DEVELOPMENTS SHOW CONTINUED MOMENTUM AND PLATFORM VALUE
Geography &
Indication Expansion
基石药业
Sugemalimab ****
E
CSTONE
PHARMACEUTICALS
(PD-L1)
●
Pfizer
EQR
Approved in China (CStone/
Pfizer), EQRx now targeting
first regulatory filings ex-US
before year-end
Cstone/Pfizer announced
China approval in added
indication (stage III non-small
cell lung cancer)
Teclistamab
(BCMA x CD3)
●
Recently
Approved
●
Janssen
Clinical data published in New
England Journal of Medicine
EU approval received in late
August; $10M milestone to
OmniAb on first sale in EU
FDA approval received in late
October; $25M milestone to
OmniAb upon first sale in the
U.S.
Batoclimab
(FcRn)
Additional
Late-Phase Trials
●
IMMUNOVANT
Now pursuing 5 indications,
all Phase 2 or Pivotal/Phase 3:
Myasthenia Gravis
Thyroid Eye Disease
Chronic Inflammatory
Demyelinating
Polyneuropathy
Graves' Disease
Warm Autoimmune
Hemolytic Anemia
M6223
(TIGIT)
Entering
Phase 2
●
Phase 2 trial started recently
for Avelumab plus other
agents, including M6223, in
urothelial carcinoma
GEN1046
(PD-L1 x 4-1BB)
40
MERCK
Phase 2 Progression
Genmab
Announced data from clinical
expansion cohorts and
progression
OmniAbView entire presentation